Classification
In the literature, the CJC-1295 (no DAC) / Ipamorelin combination is classified as a research blend of two peptides with mapped interactions at GHRH-R (CJC-1295) and at GHS-R1a, the ghrelin receptor (Ipamorelin). The presentation is RUO and concerns laboratory models of GH-axis receptor classification.
Markers and receptor signalling in laboratory models
The literature discusses them in relation to GHRH-R and GHS-R1a binding and downstream cAMP/PKA signalling in laboratory pituitary cell models. The reading concerns receptor markers and GH-axis markers, not outcome claims.
Thematic mapping
Related research categories: GHRH receptor pharmacology, ghrelin receptor (GHS-R1a) signalling, literature mapping of GH-axis models, and peptide molecular structure.
COA / documentation where available
Where available, batch documentation (COA) reports analytical markers of identity and purity. This article provides no practical instructions, application procedures or outcome claims.
RUO note
This article is an informational overview of the literature classification of RUO materials. It provides no directions for use, application amounts, protocols or outcome claims. For laboratory research use only. Not for human or veterinary use.